Current Affairs - Technology - Discussion

R78C is a next-generation malaria vaccine component developed to provide enhanced protection by targeting multiple stages of the malaria parasite’s lifecycle. It was created by researchers at the University of Oxford and licensed to the Serum Institute of India for large-scale manufacturing and global distribution. The vaccine uses specific antigens to improve immune response and durability of protection. This collaboration builds on previous efforts in malaria vaccine development and integrates advanced production technologies. The initiative represents a major step toward combating malaria, especially in regions where the disease remains highly prevalent and life-threatening.